Last reviewed · How we verify
WGI-0301
At a glance
| Generic name | WGI-0301 |
|---|---|
| Sponsor | Zhejiang Haichang Biotech Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC (PHASE2)
- Phase 2 Study of WGI-0301 for Advanced HCC (PHASE2)
- A Phase I First in Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of WGI-0301 in Patients With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |